5175562026-04-012026-06-305175562026-04-012026-06-30in-capmkt:OtherExpenses1Member5175562026-04-012026-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares517556PVPNOTLISTEDINE362A01016PVP VENTURES LIMITEDMain BoardEquity2026-04-012027-03-312026-08-142026-08-09INRLakhsQuarterlyFirst quarterSingle segmentReal Estate2026-08-1411:00:002026-08-1415:40:00Declaration of unmodified opinionfalsefalseThere are no default on Loans and Debt securities for the first quarter ended on 30.06.20262026-04-012026-06-30UnauditedStandalone134927000254293000389220000008260000737700089018000276800023677000131100000258120000-1085000001496200000-1496000-14960000151116000000015111600001511160002604037000100.580.58000.580.581 The above standalone unaudited Financial Results of PVP Ventures Limited ('the Company') for the quarter ended 30 June 2026 have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”) as prescribed under Section 133 of the Companies Act, 2013 and Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements Regulations), 2015, as amended, ("the Listing Regulations") which were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on 14th August 2026. The Statutory Auditors of the Company have carried out Limited Review of the results for the quarter ended 30 June 2026. <br /> 2 The Company had invested in 24,832; 22% Secured Redeemable Non-Convertible Debentures (NCDs) of Rs. 100,000 each issued by New Cyberabad City Projects Private Limited ("NCCPL"), erstwhile subsidiary and currently a related party of the Company. Further, on 16 March 2015 the said investment of Rs. 24,832 Lakhs in debentures was converted to an Interest Free Secured loan against the security of Land owned by NCCPL and Land development rights available with NCCPL , repayable on 31 March 2017 which was further extended by 10 years to 31 March 2027. A further extension of 1 year until 31 March 2028 was granted vide supplementary agreement dated 07 February 2024. The outstanding principal loan amount as on 30 June 2026 is Rs. 21,843.49 Lakhs. <br /> Though NCCPL is not carrying any business activity, based on the below-mentioned factors, the Company believes that while there could be a further extension of the tenor beyond the stipulated date of 31 March 2028, the amounts are fully recoverable and hence there is no necessity to create an allowance for Expected Credit Loss. <br /> <br /> i. Market value of a nearby land serving as a proxy to the land over which development rights held by NCCPL. <br /> ii. Business plans of NCCPL to monetise the land bank by developing residential and/or commercial properties. <br /> iii. Enforceable clause in the Share Purchase Agreement (SPA) which provides the first priority repayment of the loan based on the cash flows to be generated out of the project to be developed as stated in (ii) above. Additionally, the Company is guaranteed 50% payout from the revenues generated in excess of the loan outstanding, out of the sale/development of the aforesaid properties. <br /> <br /> The Company believes that the provisions of Section 186(1) & 188 of the Act have been complied with to the extent applicable. <br /> <br /> Further based on internal assessment/professional opinion received in this regard, the other provisions of Section 186 of the Act in respect to loans, making investments, providing guarantees and securities are not applicable to the Company as it is involved in the business of providing infrastructural facilities. <br /> 3 The Company was treating the aforesaid loan as deemed investment in subsidiary and hence was carrying the same at cost until 30 September 2023. Consequent to NCCPPL ceasing to be a subsidiary as highlighted above, the Company has carried the same at amortized cost as at 30 June 2026 in accordance with the requirements of Ind AS-109 – Financial instruments. Accordingly, the Management has carried the loan at present value by discounting the future cash flows at a rate of 8% over an estimated repayment period of 8.5 years (considering the possibility of further extension as stated above as against the balance legal tenor of 4 years). <br /> The accounting has been done in the following manner: <br /> Particulars Remarks Amount upon initial <br /> recognition Amount carried as at <br /> 30 June 2026 <br /> Carried as Loan under Non-Current financial assets Interest income has been recorded under the Effective Interest Rate (EIR) method* 11,091.29 13,785.53 <br /> <br /> Carried as Prepayment asset under other Non-Current Assets Amortization would be done in proportion of revenues accruing to the Company as per the SPA as stated in Note 2 <br /> (iii) above <br /> 10,752.20 <br /> 10,752.20 <br /> 21,843.49 <br /> <br /> <br /> <br /> 4 <br /> * An amount of Rs. 303.57 Lakhs has been recognized as Interest Income under Other Income for the quarter ended 30 June 2026. <br /> <br /> During the current quarter, the Company had acquired additional 4,263 shares representing a additional stake of 7.99% of the paid up share capital of 7Med India Private Limited (7 Med) for a consideration of Rs. 1,926.24 Lakhs. Accordingly, the Company now holds 41.23% in 7 Med. The effective date of additional investment has been considered as 1 April 2026. <br /> 5 The Company had acquired Humain Healthtech Private Limited (“HHT”) in October 2023. HHT, in turn, has two subsidiaries, namely Noble Diagnostics Private Limited (“Noble”) and Apta Medical Imaging Private Limited (“Apta”). <br /> <br /> The investment in HHT is carried at cost in the standalone financial statements and is subject to impairment assessment in accordance with Ind AS 36, Impairment of Assets. Accordingly, the Company carried out an impairment assessment of its investment in HHT based on the estimated recoverable amount, considering the future business plans and projected cash flows of the underlying business. Based on the assessment, the recoverable amount was determined to be lower than the carrying amount of the investment due to negative net-worth of Apta. <br /> <br /> Consequently, an impairment loss of Rs.1,085.00 lakhs has been recognised against the investment in HHT during the quarter ended 30 June 2026. The impairment loss has been presented as an exceptional item in the Statement of Profit and Loss. <br /> 6 As per Ind AS-108 "Operating Segment", the Company has disclosed the segment information only as part of the Consolidated audited Financial Results for the quarter ended 30 June 2026. <br /> 7 Previous period figures have been reclassified to confirm to the current period classification/presentation. <br /> <br /> Other Expenses23677000000UnauditedtrueCNGSN & Associates LLPtrue2029-01-31